Unique Serum Protein and Metabolic Patterns in Patients with Advanced Clear-Cell Renal Cell Carcinoma Undergoing Sunitinib Treatment: Insights from the Spanish Oncology Genitourinary Group Study - Takeaways - MDSpire

Unique Serum Protein and Metabolic Patterns in Patients with Advanced Clear-Cell Renal Cell Carcinoma Undergoing Sunitinib Treatment: Insights from the Spanish Oncology Genitourinary Group Study

  • By

  • Guillermo Quintás

  • Elena Sanmartín

  • Alicia Garcia-Gimenez

  • José Muñoz-Langa

  • Aida Collado

  • Cristina Suárez

  • Xavier García del Muro

  • María José Méndez-Vidal

  • José García-Sánchez

  • Carmen Salvador-Coloma

  • Nuria Laínez

  • Enrique Gallardo

  • Javier Munárriz

  • Sergio Vázquez

  • Carmen Molins

  • Jaime Font de Mora

  • Gaspar Reynés

  • April 29, 2026

  • 0 min

Share

  • 1

    This study identifies serum proteins and metabolic patterns as potential biomarkers for predicting outcomes in metastatic clear cell renal cell carcinoma.

  • 2

    Higher levels of interleukin-6, arginase-1, and S100A9 are significant predictors of shorter overall survival in patients undergoing sunitinib treatment.

  • 3

    Three distinct risk groups were defined based on S100A9 and IL-6 levels, correlating with poor, intermediate, and favorable prognoses.

  • 4

    Metabolomic analysis revealed that elevated tryptophan metabolites are associated with poorer progression-free survival in CCRCC patients.

  • 5

    The study emphasizes the importance of serum proteins and metabolites in stratifying patients and predicting treatment responses in advanced CCRCC.

Original Source(s)

Unique Serum Protein and Metabolic Patterns in Patients with Advanced Clear-Cell Renal Cell Carcinoma Undergoing Sunitinib Treatment: Insights from the Spanish Oncology Genitourinary Group Study

  • by Guillermo Quintás, Elena Sanmartín, Alicia Garcia-Gimenez, José Muñoz-Langa, Aida Collado, Cristina Suárez, Xavier García del Muro, María José Méndez-Vidal, José García-Sánchez, Carmen Salvador-Coloma, Nuria Laínez, Enrique Gallardo, Javier Munárriz, Sergio Vázquez, Carmen Molins, Jaime Font de Mora, Gaspar Reynés

  • April 29, 2026

Related Content

Biotech exec Jeremy Levin on the industry’s strategic turning point

Case Report: First description of an intracranial “NET” in ROHHAD syndrome; time to rename to the ROHHAD-NeCT syndrome?

MRI perfusion in evaluating ovarian masses: diagnostic performance of wash out rate